Overview

A Study of LY2623091 in Participants With High Blood Pressure

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Mineralocorticoid Receptor Antagonists
Mineralocorticoids
Spironolactone
Tadalafil